Indian DME patients get safety check on approved eye drug

NCT ID NCT05511038

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study checked the safety of aflibercept eye injections in 100 Indian adults with diabetic macular edema (DME), a diabetes complication that causes vision loss. Participants received injections every 4 weeks for 5 months, then every 8 weeks for a total of 48 weeks. The main goal was to track any side effects, and the study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Disha Eye Hospitals

    Kolkata, West Bengal, 700120, India

  • Dr. R.P. Centre for Ophthalmic Sciences, AIIMS

    New Delhi, National Capital Territory of Delhi, 110029, India

  • L.V. Prasad Eye Institute

    Hyderabad, Andhra Pradesh, 500034, India

  • Lotus Eye Hospital and Institute

    Coimbatore, Tamil Nadu, 641014, India

  • M & J Western Regional Institute of Ophthalmology

    Ahmedabad, Gujarat, 380016, India

  • Medical Research Foundation, Sankara Nethralaya

    Chennai, Tamil Nadu, 600006, India

  • Narayana Nethralaya

    Bengaluru, Karnataka, 560010, India

  • Post Graduate Institute of Medical Education and Research

    Chandigarh, 160012, India

  • Raghudeep Eye Hospital

    Ahmedabad, Gujarat, 380052, India

  • Sankara Eye Hospital

    Bengaluru, Karnataka, 560037, India

Conditions

Explore the condition pages connected to this study.